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Abstract
Proteinuria is a defining criterion for the diagnosis of pre-eclampsia. The amount of protein lost per
day has been thought by some to predict both maternal and fetal outcome. The systematic review
of 16 primary papers including over 6700 patients by Thangaratinam and colleagues published this
month in BMC Medicine suggests otherwise. This finding may influence our management of pre-
eclampsia.
Commentary
Proteinuria has been proposed and studied as both an
indicator of severity of disease and as a predictor of out-
come in pre-eclampsia. Many clinicians still make major
management decisions based on the degree of proteinuria
in such patients. The systematic review by Thangaratinam
and colleagues [1] published this month in BMC Medi-
cine suggests however that proteinuria is a poor predictor
of either maternal or fetal complications in women with
pre-eclampsia, and provides information that may have
significant clinical implications.
Pre-eclampsia affects 2 to 3% of all pregnancies and is
responsible for about 60,000 maternal deaths every year,
mainly in poor countries [2]. Annually only 10 of these
deaths occur in the UK [3], approximately 40 to 50 in the
USA [4], while in comparison more than 200 occur in
South Africa [5]. The only known cure for pre-eclampsia is
delivery of the placenta. This creates a conflict of interest
between the individuals on either side of the placenta: the
mother stands to benefit from early delivery, while the
baby may suffer complications of prematurity if born too
early. Conservative management of pre-eclampsia to gain
time for the baby to mature inevitably places the mother
at risk [6]. Pre-eclampsia is usually a progressive disease,
but the rate of progression and the occurrence of cata-
strophic complications such as eclampsia, cerebrovascular
accident, severe HELLP syndrome, pulmonary edema or
renal failure are difficult to predict. Any marker which
could reliably predict the likelihood of serious complica-
tions would be very valuable for helping choose the opti-
mal time for delivery.
Proteinuria is a defining dysfunction of pre-eclampsia [7].
Quantitation of a timed collection has been the gold
standard for many decades and is expressed as the amount
of protein excreted in the urine per unit time. Twenty-
four-hour specimens have been traditionally used, but
more recently 12-hour collections (and even 2-hour col-
lections) have been validated [8]. The urinary protein:cre-
atinine ratio is used in some institutions instead of a
timed protein collection [9], with some finding it to be
equally useful in determining pathologic proteinuria with
the advantage of not requiring a timed collection, while
others have not been as confident [10]. A 24-hour collec-
tion remains the standard of care in the USA [7].
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The severity of the proteinuria in pre-eclampsia has been
regarded by some as a predictor of adverse outcomes for
the mother [11]. Others have been less sanguine about the
relationship [12]. A reliable correlation between the level
of proteinuria and severity of pre-eclamptic complications
would be extremely valuable for clinical decision making.
The review by Thangaratinam et al [1] reported in this
issue sets a new standard for systematically searching for,
evaluating and aggregating the results of studies of this
kind. The results are disappointing in that the correlation
found between level of proteinuria and severity of clinical
disease was insufficiently reliable to be clinically useful.
The authors reported that from a fetal point of view, the
only statistically significant findings were that proteinuria
of 5 g/24 h in a timed specimen, or 1+ and 3+ in a dipstick
specimen, predicted stillbirth with a likelihood ratio for
the positive result of 1.3 to 2.3 ('little useful' to 'somewhat
useful'). Maternal outcomes fared equally poorly. The
same group of authors has previously reported on another
biochemical marker, serum urate, with similarly disap-
pointing results [13].
Despite the rigor and efforts to determine the quality of
the studies included in the current review, practice differ-
ences, equipment changes, and definitions of pre-eclamp-
sia could have influenced the diagnosis (and
management) of pre-eclampsia over the time period of
the studies used. Thirty years ago changes in systolic pres-
sure and diastolic pressure during gestation were being
used to define pre-eclampsia (the so-called 30/15 rule)
and if the diagnosis of pre-eclampsia is differently defined
in different studies the validity of the result may be dimin-
ished.
A very important potential confounding factor to consider
in studies of the kind reviewed, is that the test result (in
this case severe proteinuria), particularly in the earlier
studies, may have dictated management. In the USA at
least, proteinuria of 5 g or more per 24 hours is one of the
diagnostic criteria for severe pre-eclampsia [7]. If women
were delivered earlier as a result of a positive test for severe
proteinuria then that test cannot be stated to have been
used to predict outcome, since its result was used to inter-
vene and thus influence the outcome. Earlier delivery pre-
cipitated by a positive test result may, for example, reduce
maternal complications (leading to an underestimation
of the predictive value of the test), or increase perinatal
morbidity due to prematurity, leading to an overestima-
tion. The test would technically have an association with
the outcome, rather than a predictive capability.
Despite these limitations, this metanalysis appears to con-
firm what clinicians have suspected for a long time. The
degree of proteinuria alone does not have a strong associ-
ation with adverse outcome. Maternal and fetal clinical
condition and gestational age, complemented by hemato-
logic and biochemical parameters, should for the time
being remain the primary determinants for timing deliv-
ery in women with pre-eclampsia.
As the results of observational studies may systematically
over- or underestimate the predictive value of tests as dis-
cussed above, a randomized trial of knowledge versus no
knowledge of the level of proteinuria to guide manage-
ment would be justified.
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